Innovotech Expands to U.S. Markets with OTCQB Listing Under IOTCF

Innovotech Inc., a diversified life sciences technology company specializing in applied microbiology, analytical chemistry, and regulated laboratory services, has achieved a significant milestone by commencing trading on the OTCQB Market in the United States under the symbol IOTCF. This strategic move, announced via a press release on www.newmediawire.com, allows the Edmonton-based company to more effectively engage with U.S. investors as it builds a larger, more diversified life sciences platform, according to CEO Craig Milne. The company's shares will continue to trade on the TSX Venture Exchange under the symbol IOT, maintaining its Canadian presence while expanding its reach into the American financial markets.

The company's momentum is supported by strong operational progress and financial performance in 2025, including a significant increase in revenues driven by both organic growth and the full-year contribution from its acquisition of Keystone Labs Inc. Innovotech recently reported consistent revenues across all quarters, reflecting improved scale, operational execution, and a more diversified revenue base. The successful integration of Keystone has materially expanded its analytical chemistry and testing capabilities while strengthening its Canadian customer base. Furthermore, the company has simplified its corporate structure through amalgamation, positioned itself as a single, integrated laboratory platform, and strengthened its balance sheet through warrant exercises and a convertible debenture issuance to support equipment purchases and strategic initiatives.

Innovotech's differentiation lies in its depth of expertise in antimicrobial testing and biofilm-related research, supported by accredited quality systems and the ability to execute complex, custom testing programs. The company manufactures and sells laboratory consumables, including its globally used MBEC Assay® platform for biofilm and antimicrobial research, and maintains an active R&D program focused on expanding assay offerings and advancing proprietary technologies like its InnovoSIL™ antimicrobial silver platform. As it enters 2026, Innovotech is focused on continued organic growth, expansion of service offerings, disciplined execution of strategic priorities, and evaluating acquisition opportunities while expanding investor outreach efforts in the United States following its OTCQB listing.